» Articles » PMID: 17763350

Feasibility of Multiple-mouse Dynamic Contrast-enhanced MRI

Overview
Journal Magn Reson Med
Publisher Wiley
Specialty Radiology
Date 2007 Sep 1
PMID 17763350
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Dynamic contrast-enhanced (DCE-) MRI is often used to evaluate the response to experimental antiangiogenic therapies in small animal models of cancer. Unfortunately, DCE-MRI studies often require a substantial investment of both time and money to achieve the desired level of statistical significance. Multiple-mouse MRI has previously been used to improve imaging efficiency, but its feasibility for DCE-MRI has not been investigated. The purpose of this work was to determine if multiple-mouse DCE-MRI is feasible when using gadolinium-based contrast agents with a low molecular weight. A population of tumor-bearing mice was scanned using two four-element arrays and a single-coil configuration on a 4.7T, 40 cm bore Bruker Biospec MRI scanner. Pharmacokinetic parameters were calculated and compared to determine if a significant difference between methodologies existed. With both four-animal imaging configurations, animal throughput accelerations of just less than three were achieved and quantitative data were not significantly different than from single-animal acquisitions.

Citing Articles

Quantitative Phenotyping of Embryonic Heart Pathophysiology Using Hemoglobin Contrast Subtraction Angiography to Screen Human Cardiomyopathies.

Deniz E, Jonas S, Khokha M, Choma M Front Physiol. 2019; 10:1197.

PMID: 31620018 PMC: 6763566. DOI: 10.3389/fphys.2019.01197.


Feasibility of multianimal hyperpolarized (13) C MRS.

Ramirez M, Lee J, Walker C, Chen Y, Kingsley C, de la Cerda J Magn Reson Med. 2014; 73(5):1726-32.

PMID: 24903532 PMC: 4257893. DOI: 10.1002/mrm.25307.


A throughput-optimized array system for multiple-mouse MRI.

Ramirez M, Lai S, Bankson J NMR Biomed. 2012; 26(3):237-47.

PMID: 22887122 PMC: 3543508. DOI: 10.1002/nbm.2841.


Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer.

Schwartz D, Bankson J, Lemos Jr R, Lai S, Thittai A, He Y Mol Cancer Ther. 2010; 9(7):2057-67.

PMID: 20587661 PMC: 2935253. DOI: 10.1158/1535-7163.MCT-09-0768.


The influence of temporal resolution in determining pharmacokinetic parameters from DCE-MRI data.

Heisen M, Fan X, Buurman J, Van Riel N, Karczmar G, Romeny B Magn Reson Med. 2010; 63(3):811-6.

PMID: 20187187 PMC: 3076555. DOI: 10.1002/mrm.22171.